Author/Authors :
Dooghaie Moghadam, Arash Research Institute for Gastroenterology and Liver Diseases - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Eslami , Pegah Research Institute for Gastroenterology and Liver Diseases - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Dowlati Beirami , Amirreza Research Institute for Gastroenterology and Liver Diseases - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Iravani, Shahrokh Research Center for Cancer Screening and Epidemiology - AJA University of Medical Sciences, Tehran, Iran , Farokhi, Ermia Liver Transplantation Research Center - Tehran University of Medical Sciences, Tehran, Iran , Mansour-Ghanaei , Alireza Gastrointestinal and Liver Diseases Research Center (GLDRC) - Guilan University of Medical Sciences, Guilan, Iran , Hashemi , Mahmood Reza Gastroenterology and Hepatobiliary Research Center - AJA University of Medical Sciences, Tehran, Iran , Aghajanpoor Pasha, Morteza Gastroenterology and Hepatobiliary Research Center - AJA University of Medical Sciences, Tehran, Iran , Mehrvar, Azim Research Center for Cancer Screening and Epidemiology - AJA University of Medical Sciences, Tehran, Iran , Nassiri-Toosi, Mohssen
Abstract :
Currently, liver transplantation (LT) is considered as the only option for the treatment
of patients with various causes of liver failure, including patients with chronic hepatitis
B virus (HBV) infections. Overall, patients with HBV who undergo LT are at increased
risk of hepatitis B infection recurrence. Although the current knowledge regarding
the pathophysiology of this infection has been dramatically increased over the past few
decades, it is still considered a complex disease process with varying degrees of clinical
characteristics and changing patterns over time. There are various treatment strategies for
preventing HBV recurrence in the LT setting. Generally, these regimens include oral nucleoside/
nucleotide analogues (NAs), hepatitis B immune globulin (HBIG), and vaccines or the
combination of these drugs. The treatment strategy of choice should be based on cost-
effectiveness, along with other patients underlying conditions. In this case, studies indicate
that potent NAs are more cost-effective than HBIG in most case scenarios. In this article,
we aimed to review the general medications used in the prophylaxis of the recurrence of
HBV infection after LT.
